What is the Impact Factor of Translational Lung Cancer Research?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Translational Lung Cancer Research is 3.40, ranking in quartile Q2 of Web of Science (SCIE).

Is Translational Lung Cancer Research indexed in Web of Science or Scopus?

Yes, Translational Lung Cancer Research is indexed in Web of Science (SCIE, Q2 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 0.987 (Q2) and an H-index of 78.

Who publishes Translational Lung Cancer Research and what is the Article Processing Charge (APC)?

Translational Lung Cancer Research is published by Society for Translational Medicine (STM). The estimated Article Processing Charge (APC) is approximately $3,407 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Translational Lung Cancer Research?

The official ISO-4 abbreviation of Translational Lung Cancer Research is "TRANSL LUNG CANCER R". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q2Scopus Q2SCImago #4,997Gold OA

Translational Lung Cancer Research

Abbreviation (ISO):TRANSL LUNG CANCER R

•

Identifier (ISSN):2218-6751(Online)

•

Publisher:Society for Translational Medicine (STM)

Official Website Submission Portal Compare

Clarivate IF (2026)

3.4↓ -0.1

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Translational Lung Cancer Research

WoS Q2

Annual Impact Factor Metric

Current (2026):3.4

Scopus SJR & RankScopus Q2

0.987

#4,997

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

78 papers with at least that number of citations each

WoS: SCIE / JCRQ2

Self-Citation Rate5%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessGold OA

354articles/year

100% Gold OA•92.43% Original Research

Aims & Scope

Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.

Topics Covered (Recognized by AI)

Medicine99.4%Internal medicine96.1%Pathology92.5%Biology91.3%Oncology88.4%Lung cancer85.2%Genetics81%Cancer70.8%Surgery54.8%Chemistry45.9%Biochemistry43.3%Radiology35.7%Immunology33.1%Cancer research33%Philosophy27.4%Linguistics26.2%Lung25.3%Bioinformatics25.1%Gene25%Mathematics23%

Primary Research Areas

Medicine Oncology

Official Website NLM PubMed Catalog Submission Portal SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

ONCOLOGY

Rank148/333

IndexSCIE

JCRSCIE2026

RESPIRATORY SYSTEM

Rank36/107

IndexSCIE

JCISCIE2026

ONCOLOGY

Rank129/333

IndexSCIE

JCISCIE2026

RESPIRATORY SYSTEM

Rank40/107

IndexSCIE

Category	Index	Rank	Quartile
ONCOLOGY	JCRSCIE	148/333	Q2
RESPIRATORY SYSTEM	JCRSCIE	36/107	Q2
ONCOLOGY	JCISCIE	129/333	Q2
RESPIRATORY SYSTEM	JCISCIE	40/107	Q2

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF3.4

Articles / Year266

Total Citations37

2025

IF3.5

Articles / Year430

Total Citations892

2024

IF4

Articles / Year324

Total Citations1,452

2023

IF4

Articles / Year244

Total Citations2,035

2022

IF4.726

Articles / Year233

Total Citations3,308

Year	Impact Factor	Articles / Year	Total Citations
2026	3.4	266	37
2025	3.5	430	892
2024	4	324	1,452
2023	4	244	2,035
2022	4.726	233	3,308
2021	6.498	389	8,572
2020	5.132	302	6,690
2019	4.806	189	5,549
2018	0	195	5,502
2017	—	93	2,923
2016	—	92	4,920
2014	—	1	0

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #4,997Scopus Q2SCImago Profile

Scopus Coverage:2012-2026

•

Scopus Broad Areas:Medicine

Scopus Citation Rank (SJR)Q2

0.987

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2

Citations / Doc (2 years)

2.72

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,407 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations2,437

3-Year Documents793

Citable Documents655

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate37.7%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

OncologyQ2

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 5%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

3区ONCOLOGY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Translational Lung Cancer Research (abbr: TRANSL LUNG CANCER R) is a peer-reviewed international scholarly journal in the field of Medicine, published by Society for Translational Medicine (STM) in Hong Kong since 2012. The periodical holds a Journal Impact Factor (JIF) of 3.40, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 0.987 (Q2), an H-index of 78.

The journal enforces rigorous peer evaluation with a publication frequency of monthly, an annual output of approximately 354 scientific articles. In terms of accessibility and author fees, it operates under the Gold OA model with an estimated APC of $3,407 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.